Doxepin | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
Doxepin | hsa00190 | Oxidative phosphorylation | 5.12E-04 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Doxepin | hsa00500 | Starch and sucrose metabolism | 1.79E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
Doxepin | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
Doxepin | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | |
Doxepin | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Doxepin | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | |
Doxepin | hsa00830 | Retinol metabolism | 3.15E-02 | 1 | P00325 | ADH1B | More | |
Doxepin | hsa00970 | Aminoacyl-tRNA biosynthesis | 7.90E-03 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | |
Doxepin | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
Doxepin | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
Doxepin | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
Doxepin | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
Doxepin | hsa02010 | ABC transporters | 1.98E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | |
Doxepin | hsa03020 | RNA polymerase | 1.31E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | |
Doxepin | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
Doxepin | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
Doxepin | hsa04062 | Chemokine signaling pathway | 3.93E-03 | 10 | P25024, P25025, P47992, Q9UBD3, P07948, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, XCL1, XCL2, LYN, GNG5, GNG10, ARRB1, ITK, GSK3B | More | |
Doxepin | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | |
Doxepin | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
Doxepin | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
Doxepin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
Doxepin | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
Doxepin | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | |
Doxepin | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
Doxepin | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
Doxepin | hsa04610 | Complement and coagulation cascades | 5.18E-06 | 1 | P0C0L4 | C4A | More | |
Doxepin | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
Doxepin | hsa04613 | Neutrophil extracellular trap formation | 3.76E-04 | 10 | P11215, Q13547, P04908, Q93077, P58876, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
Doxepin | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
Doxepin | hsa04640 | Hematopoietic cell lineage | 3.69E-02 | 4 | P21926, P07766, P01730, P09564 | CD9, CD3E, CD4, CD7 | More | |
Doxepin | hsa04650 | Natural killer cell mediated cytotoxicity | 3.19E-06 | 10 | P01375, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | |
Doxepin | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
Doxepin | hsa04660 | T cell receptor signaling pathway | 2.78E-02 | 7 | P01375, Q08881, P20963, Q13191, P06239, Q16539, P49841 | TNF, ITK, CD247, CBLB, LCK, MAPK14, GSK3B | More | |
Doxepin | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
Doxepin | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
Doxepin | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
Doxepin | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
Doxepin | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | |
Doxepin | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
Doxepin | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
Doxepin | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
Doxepin | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
Doxepin | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
Doxepin | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
Doxepin | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
Doxepin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Doxepin | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | |
Doxepin | hsa04966 | Collecting duct acid secretion | 1.29E-03 | 2 | P02730, P00918 | SLC4A1, CA2 | More | |
Doxepin | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
Doxepin | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | |
Doxepin | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
Doxepin | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
Doxepin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
Doxepin | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
Doxepin | hsa05034 | Alcoholism | 2.10E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
Doxepin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.11E-02 | 4 | Q16539, P25024, P25025, P07948 | MAPK14, CXCR1, CXCR2, LYN | More | |
Doxepin | hsa05133 | Pertussis | 3.60E-03 | 1 | P0C0L4 | C4A | More | |
Doxepin | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | |
Doxepin | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | |
Doxepin | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
Doxepin | hsa05144 | Malaria | 1.06E-03 | 4 | P60033, P01375, P35443, P26718 | CD81, TNF, THBS4, KLRK1 | More | |
Doxepin | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
Doxepin | hsa05150 | Staphylococcus aureus infection | 1.16E-03 | 6 | P0C0L4, P13646, Q14532, P59665, P59666, P49913 | C4A, KRT13, KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | |
Doxepin | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
Doxepin | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | |
Doxepin | hsa05168 | Herpes simplex virus 1 infection | 6.00E-04 | 16 | P25963, P01568, Q05823, P42224, Q07955, Q01130, Q13243, Q13489, Q9Y2A4, Q13398, P51522, Q9HCX3, P17038, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF443, ZNF211, ZNF83, ZNF304, ZNF43, ZNF140, ZNF189, ZNF212 | More | |
Doxepin | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
Doxepin | hsa05203 | Viral carcinogenesis | 6.44E-03 | 4 | Q13547, P58876, Q16778, O60814 | HDAC1, H2BC5, HIST2H2BE, H2BC12 | More | |
Doxepin | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
Doxepin | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
Doxepin | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | |
Doxepin | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
Doxepin | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | |
Doxepin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 1.09E-02 | 4 | P07766, P06239, Q9HC35, P01730 | CD3E, LCK, EML4, CD4 | More | |
Doxepin | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
Doxepin | hsa05322 | Systemic lupus erythematosus | 1.18E-02 | 3 | P58876, Q16778, O60814 | H2BC5, HIST2H2BE, H2BC12 | More | |
Doxepin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
Doxepin | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
Doxepin | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | |
Doxepin | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.71E-03 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | |
Doxepin | hsa05414 | Dilated cardiomyopathy | 2.58E-03 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
Doxepin | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | |
Doxepin | hsa05418 | Fluid shear stress and atherosclerosis | 3.61E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |